



Microfluidics

Customer Spotlight Webinar Series

- Research on tropical medicine and vaccine effectiveness around the world -

Webinar Date & Time

December 11, 2023
2:00 - 3:00 pm (JST)

[Register >](#)



<https://attendee.gotowebinar.com/register/3593397948689586016?source=flyer>

- Seminars are in English only
- For those unable to attend live, you can register to view the recording on demand after the event.

Questions?

Please contact:

Info-japan@standardbio.com

Standard BioTools K.K.

formerly known as
Fluidigm K.K.

Message

Globally 2.5 million people, including children die every year due to pneumonia mostly in resource-limited regions. *Streptococcus pneumoniae* is the major pathogen. Dr. Bhim's main research is focused on this pathogen. They use a high throughput nanofluidic assay (Biomark system) to identify various vaccine and non-vaccine serotypes (total ≥ 100), and study their epidemiology, vaccine effectiveness, and interaction when two or more that two serotypes are present at the same time. Besides, They are developing and validating novel quantitative (multiplex bead-based) and qualitative (opsonophagocytic) assays for the assessment of pneumococcal vaccines. These assays not only help in post-licensure evaluation of the vaccines in various specific populations, such as the elderly and the children with sickle cell anaemia (which are generally not done at the time of licensure), but also helps to assess the immunogenicity of novel vaccines.

Moderator



Rieko Ikeda
Regional Marketing Manager

Introduction



2:00 - 2:15 pm

Advantages of Microfluidics Technology and Biomark X9 System

Tatsuro Nakajima
Team Leader
Field Application Scientist

Guest Speaker



2:15 - 2:55 pm

Use of a high-throughput microfluidic platform for molecular serotyping of pneumococci

Bhim Gopal Dhouhadel, MD, Ph.D.
Associate Professor, School of Tropical Medicine and Global Health, Nagasaki University